Metastatic Breast Cancer-Specific Prognostic Tool
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Doxil/Caelyx BE Study
- Status
- COMPLETED
- Phase
- PHASE1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
BRaziLian outcomE for metAStatic breasT Cancer
- Status
- UNKNOWN
- Phase
- N/A
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
- Status
- RECRUITING
- Phase
- N/A
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Onvansertib + Paclitaxel In TNBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
- Status
- COMPLETED
- Phase
- N/A
Comprehensive Outcomes for After Cancer Health
- Status
- RECRUITING
- Phase
- NA
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
- Status
- UNKNOWN
- Phase
- PHASE3
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2